(1R)-6-methoxy-1-methyl-1-trifluoromethylisochroman-7-carbaldehyde | 225526-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (1R)-6-methoxy-1-methyl-1-trifluoromethylisochroman-7-carbaldehyde
• 英文别名: 6-methoxy-1-methyl-1-trifluoromethyl-isochroman-7-methylaldehyde；(1R)-6-Methoxy-1-methyl-1-(trifluoromethyl)-3,4-dihydro-1H-2-benzopyran-7-carbaldehyde；(1R)-6-methoxy-1-methyl-1-(trifluoromethyl)-3,4-dihydroisochromene-7-carbaldehyde
• CAS: 225526-60-3
• 化学式: C₁₃H₁₃F₃O₃
• 分子量: 274.24
• InChiKey: RDOKLDFJIBLNAR-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  cis-(+/-)-2-phenylpiperidin-3-ylamine 、 (1R)-6-methoxy-1-methyl-1-trifluoromethylisochroman-7-carbaldehyde 在 cis-(+/-)-2-phenylpiperidin-3-ylamine 作用下， 生成 (2S,3S)-3-[(1R)-6-methoxy-1-methyl-1-trifluoromethylisochroman-7-yl]methylamino-2-phenylpiperidine
  参考文献：
  名称：

  Bioorg. Med. Chem. 2008, 16, 7193-7205

  摘要：

  DOI：
• 作为产物：
  描述：

  (1R)-6-methoxy-1-methyl-1-trifluoromethyl-isochroman 、 二氯甲基正丁醚 在 二氯甲基正丁醚 作用下， 以54的产率得到(1R)-6-methoxy-1-methyl-1-trifluoromethylisochroman-7-carbaldehyde
  参考文献：
  名称：

  Bioorg. Med. Chem. 2008, 16, 7193-7205

  摘要：

  DOI：

文献信息

• Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
  申请人：Pfizer Inc.

  公开号：US20030208079A1

  公开（公告）日：2003-11-06

  This invention provides a compound of the formula: 1 and its pharmaceutically acceptable salts, wherein R 1 is C 1 -C 6 alkyl; R 2 is hydrogen, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl or phenyl; R 3 is hydrogen or halo; R 4 and R 5 are independently hydrogen, C 1 -C 6 alkyl or halo C 1 -C 6 alkyl; and n is one, two or three. These compounds are useful as analgesics or anti-inflammatory agents, or in the treatment of cardiovascular diseases, allergic disorders, angiogenesis, CNS disorders, emesis, gastrointestinal disorders, sunburn, urinary incontinence, or diseases, disorders or adverse conditions caused by Helicobacter pylori, or the like, in a mammalian subject, especially humans. Intermediates for preparation of the compounds of Formula (I) are also disclosed.

  这项发明提供了以下化合物及其药用可接受的盐： 1 其中R 1 为C 1 -C 6 烷基；R 2 为氢、C 1 -C 6 烷基、卤代C 1 -C 6 烷基或苯基；R 3 为氢或卤素；R 4 和R 5 独立地为氢、C 1 -C 6 烷基或卤代C 1 -C 6 烷基；n为一、二或三。 这些化合物可用作镇痛剂或抗炎药，或用于治疗心血管疾病、过敏性疾病、血管生成、中枢神经系统疾病、呕吐、胃肠道疾病、晒伤、尿失禁，或由幽门螺杆菌等引起的疾病、疾病或不良状况，尤其是在哺乳动物主体，特别是人类中。还公开了制备式(I)化合物的中间体。
• Reduction of naphthalene concentration in aromatic fluids
  申请人：Luo Shifang

  公开号：US20050234275A1

  公开（公告）日：2005-10-20

  A process for reducing naphthalene concentration in a naphthalene containing aromatic fluid, the process comprises hydrogenating at least a portion of the naphthalene in the presence of a Group VIII metal catalyst at a temperature from 50° C. to 110° C. to form tetrahydronaphthalene.

  一种降低含有萘的芳香流体中萘浓度的方法，该方法包括在存在第VIII族金属催化剂的情况下，将至少部分萘加氢在温度为50°C至110°C的条件下，形成四氢萘。
• [EN] 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES<br/>[FR] DERIVES DE 3-AMINO-2-PHENYLPYRROLIDINE
  申请人：PFIZER PROD INC

  公开号：WO2005115976A1

  公开（公告）日：2005-12-08

  3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed.

  抗NK-1的3-氨基-2-苯基吡咯烷化合物，以及包含这些化合物的药物组合物和治疗方法被披露。
• Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist ‘CJ-17,493’
  作者：Yuji Shishido、Hiroaki Wakabayashi、Hiroki Koike、Naomi Ueno、Seiji Nukui、Tatsuya Yamagishi、Yoshinori Murata、Fumiharu Naganeo、Mayumi Mizutani、Kaoru Shimada、Yoshiko Fujiwara、Ayano Sakakibara、Osamu Suga、Rinko Kusano、Satoko Ueda、Yoshihito Kanai、Megumi Tsuchiya、Kunio Satake

  DOI：10.1016/j.bmc.2008.06.047

  日期：2008.8

  A novel central nervous system (CNS) selective neurokinin-1 (NK1) receptor antagonist, (2S, 3S)-3-[(1R)-6-methoxy- 1-methyl-1-trifluoromethylisochroman-7-yl]-methylamino-2-phenylpiperidine 'CJ-17,493'( compound (+)-1), was synthesized stereoselectively using a kinetic resolution by lipase-PS as a key step. Compound (+)-1 displayed high and selective affinity (K-i = 0.2 nM) for the human NK1 receptor in IM-9 cells, potent activity in the [Sar(9), Met(O-2)(11)] SP-induced gerbil tapping model (ED50 = 0.04 mg/kg, sc) and in the ferret cisplatin (10 mg/kg, ip)-induced anti-emetic activity model (vomiting: ED90 = 0.07 mg/kg, sc), all levels of activity comparable with those of CP-122,721. In addition, compound (+)-1 exhibited linear pharmacokinetics rather than the super dose-proportionality of CP-122,721 and this result provides a potential solution for the clinical issue observed with CP-122,721. (C) 2008 Elsevier Ltd. All rights reserved.
• PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS
  申请人：PFIZER INC.

  公开号：EP1032571A1

  公开（公告）日：2000-09-06